Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

Rhea-AI Summary

Larimar Therapeutics (Nasdaq: LRMR) announced participation in the Guggenheim 4th Annual Immunology & Neurology Day on November 14-15, 2022. Management will engage in a virtual fireside chat and hold 1x1 investor meetings.

The fireside chat is scheduled for November 15 from 9:00 – 9:25 AM ET. Investors can access the chat via the provided webcast link. Larimar focuses on developing treatments for rare diseases, particularly Friedreich's ataxia, using its intracellular delivery platform.

BALA CYNWYD, Pa., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that company management will participate in a virtual fireside chat and 1x1 investor meetings at the Guggenheim 4^th Annual Immunology & Neurology Day, which is taking place from November 14 – 15, 2022.

Details on the fireside chat can be found below.

Date:	Tuesday, November 15, 2022
Time:	9:00 – 9:25 AM ET
Webcast link:	https://guggenheim.metameetings.net/events/neuroimmunology22/sessions/43153-larimar-therapeutics-inc/webcast?gpu_only=true&kiosk=true

About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds. For more information, please visit: https://larimartx.com.

Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569

Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715

FAQ

What event is Larimar Therapeutics participating in on November 14-15, 2022?

Larimar Therapeutics is participating in the Guggenheim 4th Annual Immunology & Neurology Day.

When is Larimar's fireside chat scheduled during the Guggenheim event?

The fireside chat is scheduled for November 15, 2022, from 9:00 – 9:25 AM ET.

How can I access the webcast for Larimar's fireside chat?

You can access the webcast for Larimar's fireside chat through this link: webcast link.

What is the focus of Larimar Therapeutics?

Larimar Therapeutics focuses on developing treatments for complex rare diseases, including Friedreich's ataxia.

What is Larimar Therapeutics' lead compound?

Larimar's lead compound is CTI-1601, aimed at treating Friedreich's ataxia.